Soluplus-solubilized citrated camptothecin - A potential drug delivery strategy in colon cancer

AAPS PharmSciTech

Volumn 13, Issue 1, 2012, Pages 59-66

  Thakral, Naveen K ^a   Ray, Alok R ^a,b   Bar Shalom, Daniel ^c   Eriksson, André Huss ^c   Majumdar, Dipak K ^d  

^a INDIAN INSTITUTE OF TECHNOLOGY DELHI   (India)

^b ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d UNIVERSITY OF DELHI   (India)

Author keywords

Caco 2; Camptothecin; Colon targeting; Eudragit S100; Solid dispersion; Soluplus

Indexed keywords

CAMPTOTHECIN; CITRIC ACID; EUDRAGIT; OXIDOREDUCTASE; POLYMER; PROTEIN P53; SOLUPLUS; UNCLASSIFIED DRUG;

AQUEOUS SOLUTION; ARTICLE; CELL CYCLE ARREST; CELL STRAIN CACO 2; COLON CANCER; CONCENTRATION RESPONSE; CRYSTALLIZATION; DIFFERENTIAL SCANNING CALORIMETRY; DISPERSION; DNA STRAND BREAKAGE; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STABILITY; HYDROGEN BOND; IN VITRO STUDY; INFRARED SPECTROSCOPY; PH; POINT MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; X RAY DIFFRACTION;

CACO-2 CELLS; CAMPTOTHECIN; CITRIC ACID; COLONIC NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; HUMANS; SOLUBILITY; X-RAY DIFFRACTION;

EID: 84861021056     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-011-9720-0     Document Type: Article

References (39)

1. Giovannucci E. Modifiable risk factors for colon cancer. Gastroenterol Clin North Am. 2002;31:925-43. (Pubitemid 35403506)
2. Kinzler KW, Vogelstein B. Colorectal tumors. In: Vogelstein B, Kinzler KW, editors. The genetic basis of human cancer. 2nd ed. New York: McGraw-Hill; 2002. p. 583-612.
3. Compton C, Hawk ET, Grochow L, Lee F, Ritter M, Niederhuber JE. Colon cancer. In: Abeloff MD, Armitage J, Niederhuber JE, Kastan MB, McKenna GW, editors. Abeloff's Clinical Oncology. Philadelphia: Churchill Livingstone; 2008. p. 1477-534.
4. Libutti SK, Saltz LB, Tepper JE. Colon cancer. In: DeVita Jr VT, Lawrence TS, Rosenberg SA, editors. DeVita, Hellman and Rosenberg's Cancer Principles and Practice of Oncology. Vol.1. Philadelphia: Lippincott Williams & Wilkins; 2008. p. 1232-84.
5. Moertel CG. Chemotherapy for colorectal cancer. N Eng J Med. 1994;330:1136-42. (Pubitemid 24118273)
6. DiPiro JT. Pharmacotherapy (a pathophysiologic approach). 7th ed. New York: McGraw-Hill Medical; 2008.
7. Wall ME, Wani MC, Cook CE, Palmer KH, Mc Phail AT, Sim GA. Plant antitumor agents: I. Isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J Am Chem Soc. 1966;88:3888-90.
8. Camptothecin. In: Wikipedia; the free encyclopedia. Accessed 25 June 2010
9. Wang JC. DNA topoisomerases. Ann Rev Biochem. 1985;54:665-97. (Pubitemid 15073661)
10. Chen AY, Liu LF. DNA topoisomerases, essential enzymes and lethal targets. Ann Rev Pharmacol Toxicol. 1994;94:194-218.
11. Scott DO, Bindra DS, Stella VJ. Plasma pharmacokinetics of the lactone and carboxylate forms of 20(S)-camptothecin in anesthetized rats. Pharm Res. 1993;10:1451-7. (Pubitemid 23302661)
12. Chourpa I, Millot JM, Stockalingum GD, Riou JF, Manfait M. Kinetics of lactone hydrolysis in antitumor drugs of camptothecin series as studied by fluorescence spectroscopy. Biochem Biophys Acta. 1998;1379:353-66. (Pubitemid 28127878)
13. Burke TG, Mi Z. Preferential binding of the carboxylate form of camptothecin by human serum albumin. Anal Biochem. 1993;212:285-7. (Pubitemid 23219487)
14. Moertel CG, Schutt AJ, Reitemeier RJ, Hahn R. Phase II study of camptothecin (NSC 100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother Rep. 1972;56:95-9.
15. Muggia FM, Creaven PJ, Hansen HH, Cohen MH, Sealwry OS. Phase 1 clinical trials of weekly and daily treatment with camptothecin (NSC 100880). Cancer Chemother Rep. 1972;56:515-21.
16. Hertzberg RP, Caranfa MJ, Holden KG, Jakas DJ, Liu LF. DNA topoisomer, topoisomerase-targeting drugs. New York: Academy Press; 1994.
17. Daoud SS, Fetouh MI, Giovanella BC. Antitumor effect of liposomes-incorporated camptothecin in human malignant xenografts. Anti-cancer Drugs. 1995;6:83-93.
18. Ertl B, Platzer P, Wirth M, Gabor F. Poly(D, L-lactic-co-glycolic acid) microspheres for sustained delivery and stabilization of camptothecin. J Controlled Rel. 1999;61:305-17. (Pubitemid 29413025)
19. Greenwald RB, Pendri A, Conover C, Gilbert C. Drug delivery systems. 2. Camptothecin 20-O-poly(ethylene glycol) ester transport forms. J Med Chem. 1996;39:1938-40. (Pubitemid 26157293)
20. Kang J, Kumat V, Yang D, Chowdhury PR, Hohl RJ. Cyclodextrin complexation, influence on the solubility, stability, and cytotoxicity of camptothecin, an antineoplastic agent. Eur J Pharm Sci. 2002;15:163-70. (Pubitemid 34155378)
21. Crowley MM, Zhang F, Repka MA, Thumma S, Upadhye SB, Battu SK, et al. Pharmaceutical application of hot melt extrusion, part 1. Drug Dev Ind Pharm. 2007;33:909-26.
22. Thakral NK, Ray AR, Majumdar DK. Eudragit S-100 entrapped chitosan microspheres of valdecoxib for colon cancer. J Mater Sci Mater Med. 2010;21(9):2691-9.
23. Li SP, Feld KM, Kowarski CR. Preparation and evaluation of Eudragit acrylic resin from controlled drug release of pseudoephedrine hydrochloride. Drug Dev Ind Pharm. 1991;17:1655-83.
24. Thakral NK, Ray AR, Bar-Shalom D, Eriksson AH, Majumdar DK. The quest for targeted delivery in colon cancer: mucoadhesive valdecoxib microspheres. Int J Nanomedicine. 2011;6:1057-68.
25. Warner DL, Burke TG. Simple and versatile high-performance liquid chromatographic method for the simultaneous quantitation of the lactone and carboxylate forms of camptothecin anticancer drugs. J Chromatogr. 1997;691:161-71. (Pubitemid 27168851)
26. Slade L, Levine H. A food polymer science approach to structure-property relationships in aqueous food systems: nonequilibrium behavior of carbohydrate-water system. In: Slade L, Levine H, editors. Water relationships in food. New York: Plenum Press; 1991. p. 29-101.
27. Schiller C, Fröhlich CP, Giessmann T, Siegmund W, Mönnikes H, Hosten N, et al. Intestinal fluid volumes and transit of dosage forms as assessed by magnetic resonance imaging. Aliment Pharmacol Ther. 2005;22:971-9. (Pubitemid 41634879)
28. Indian Pharmacopoeia. The Indian Pharmacopoeia Commission, Ghaziabad, Ministry of Health & Family Welfare. Government India. 2010;1:559-60.
29. Anderberg EK, Artursson P. Epithelial transport of drugs in cell culture: VIII. Effects of the pharmaceutical surfactant excipient sodium dodecyl sulfate on cell membrane and tight junctional permeability in human intestinal epithelial (Caco-2) cells. J Pharm Sci. 1993;82:392-8. (Pubitemid 23150434)
30. Larsen M, Larsen BB, Frolund B, Nielsen CU. Transport of amino acids and GABA analogues via the human protoncoupled amino acid transporter, hPAT1, characterization of conditions for affinity and transport experiments in Caco-2 cells. Eur J Pharm Sci. 2008;35:86-95.
31. Wike-Hooley JL, van den Berg AP, van der Zee J, Reinhold HS. Human tumor pH and its variation. Eur J Cancer Clin Oncol. 1985;21:785-91.
32. Hartwell L. Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells. Cell. 1993;71:543-6.
33. Nelson WG, Kastan MB. DNA strand break, the DNA template alterations that trigger p53-dependant DNA damage response pathways. Mol Cell Biol. 1994;14:1815-23. (Pubitemid 24074576)
34. Slichenmyer WJ, Nelson WG, Slebos RJ, Kastan MB. Loss of a p53-associated G1 checkpoint does not increase cell survival following DNA damage. Cancer Res. 1993;53:4164-8. (Pubitemid 24146760)
35. Rodrigues NR, Rowan A, Smith ME, Kerr IB, Bodmer WF, Gannon JV, et al. p53 mutation in colorectal cancer. Proc Natl Acad Sci USA. 1990;87:7555-9.
36. Liu Y, Bodmar WF. Analysis of p53 mutations and their expression in 56 colorectal cell lines. Proc Natl Acad Sci USA. 2006;103:976-81. (Pubitemid 43212207)
37. Konopa J. G2 block induced by DNA crosslinking agents and its possible consequences. Biochem Pharmacol. 1988;37:2303-9.
38. Han Z, Chatterjee D, Ming He D, Early J, Pantazis P, Wyche JH, et al. Evidence for a G2 checkpoint in p53-independent apoptosis induction by X-irradiation. Mol Cell Bio. 1995;15:5849-57.
39. Goldwasser F, Shimizu T, Jackman J, Hoki Y, O'Connor PM, Kohn KW, et al. Correlations between S and G2 arrest and the cytotoxicity of camptothecin in human colon carcinoma cells. Cancer Res. 1996;56:4430-7. (Pubitemid 26330451)